The Octave MSDA Test

Casandra

Casandra Test Code OB92433Version 1 (DRAFT)

Performing Lab

Lab Octave BioscienceLab Test ID N/A

Clinical Use

Use

The Octave MSDA Test is a serum-based, multi‑protein assay developed to quantify multiple sclerosis (MS) disease activity using objective biomarkers. Each result provides an overall Disease Activity score alongside four pathway scores (immunomodulation, neuroinflammation, myelin biology, and neuroaxonal integrity), helping clinicians assess both the likelihood and relative severity of current disease activity. The test supports establishing a measurable baseline in routine care and enables longitudinal tracking to differentiate stability from change across visits or life events. In clinical practice, results can inform treatment strategies such as initiating or switching disease‑modifying therapies by adding sensitive, complementary information to symptoms and MRI findings. Published validation shows the multi‑protein approach outperforms a single biomarker (e.g., NfL) for key activity measures, providing more comprehensive insight to guide MS management over time.

Special Instructions

Ordering is by a licensed provider; reports are delivered to the ordering provider. The test yields an overall disease activity score and four pathway scores derived from an 18‑protein panel, with longitudinal views available to aid ongoing assessment. Octave notes broad accessibility and a patient support program (Octave Cares) aiming to keep typical out‑of‑pocket costs modest, and provides a sample report by request. Results are generally available about 5–7 days after the sample is received. Testing is performed in Octave’s high‑complexity CLIA‑certified and CAP‑accredited laboratory. Clinicians can contact Octave’s clinical support team for implementation assistance and workflow integration.

Limitations

This assay quantifies serum protein biomarkers associated with MS pathophysiology and is intended to complement, not replace, clinical evaluation and neuroimaging. Results indicate the likelihood and relative severity of disease activity but do not localize lesions, determine etiology of symptoms, or establish a diagnosis. Interpretation should consider individual context, timing relative to clinical events, and other relevant findings. As with all biomarker tests, pre‑analytical and biological variability (e.g., timing of draw, comorbidities, or life changes) may influence measured concentrations. Performance characteristics reflect studied populations and endpoints; clinical decisions should integrate MRI, examination, history, and patient priorities. The assay reports a fixed set of pathway and overall scores based on 18 proteins; results outside validated use or populations may not generalize.

Test Details

New York Approved